Back to Search
Start Over
Ciliary body metastasis from renal cell carcinoma successfully treated with intravitreal bevacizumab
- Source :
- American Journal of Ophthalmology Case Reports, American Journal of Ophthalmology Case Reports, Vol 6, Iss C, Pp 61-63 (2017)
- Publication Year :
- 2017
- Publisher :
- Elsevier BV, 2017.
-
Abstract
- Purpose To report an innovative new treatment option for ciliary body tumor metastasis from renal cell carcinoma treated with intravitreal bevacizumab. Observations A 70-year-old Caucasian man presented with a ciliary body tumor as a result from metastasis from renal cell carcinoma. It was preferable to treat the ciliary body tumor in the least invasive manner possible based on the patient's health, systemic metastasis, and the invasiveness of local resection. The tumor was treated with intravitreal bevacizumab for attempted tumor regression. Complete tumor resolution occurred following three injections. Conclusions and importance There is no consensus on treatment for ciliary body metastases from renal cell carcinoma. Based on the successful result of our patient, intravitreal bevacizumab could be an acceptable treatment option for this type of intraocular tumor. It affords a relatively non-invasive method of tumor regression without undergoing major intraocular surgery.
- Subjects :
- medicine.medical_specialty
Bevacizumab
030232 urology & nephrology
Ciliary body
Metastasis
03 medical and health sciences
0302 clinical medicine
lcsh:Ophthalmology
Renal cell carcinoma
Case report
Medicine
Intravitreal bevacizumab
Intraocular tumor
Ciliary Body Tumor
business.industry
Treatment options
medicine.disease
Surgery
Ophthalmology
medicine.anatomical_structure
lcsh:RE1-994
030220 oncology & carcinogenesis
business
medicine.drug
Subjects
Details
- ISSN :
- 24519936
- Volume :
- 6
- Database :
- OpenAIRE
- Journal :
- American Journal of Ophthalmology Case Reports
- Accession number :
- edsair.doi.dedup.....c7aba9cb5ed4bd4038bf17e4217c967c
- Full Text :
- https://doi.org/10.1016/j.ajoc.2017.01.009